Trial DesignThe REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
Section snippets
Study design
The REACH Registry is an international, prospective, observational registry with an 18- to 24-month period of follow-up (Figure 1). The study will be approved by local institutional review boards and all patients will give informed consent.
Study population. Patients will be eligible for enrollment into the REACH Registry if they are aged ≥45 years with at least 1 of the following 4 criteria: any combination of at least 3 atherosclerosis risk factors (as listed in Table I), documented CAD,
Discussion
It is known that individuals presenting for the first time with any atherosclerotic disease, whether CAD, cerebrovascular disease, or PAD, are at risk for subsequent vascular events either in the same or different arterial bed.3 Consequently, there is a need to develop strategies to prevent either the primary development of these clinical syndromes or to offer therapeutic interventions that might lower long-term event rates in these vulnerable populations. Major opportunities exist
Limitations
Although this is a large, global registry of atherothrombotic disease involving many parts of the world not previously explored, there are several important limitations to this study. The enrollment of patients will be attempted to be consecutive, but because of the logistics involved on a worldwide basis, it is not possible to ensure this with enrollment logs, particularly in busy clinical practices. Nevertheless, the enrollment at each site will occur quickly, suggesting that only limited
References (24)
- et al.
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
Lancet
(1997) Peripheral arterial disease in the catheterization laboratory: an underdetected and undertreated risk factor
Mayo Clin Proc
(2004)- et al.
Secondary prevention strategies in ischemic stroke: identification and optimal management of modifiable risk factors
Mayo Clin Proc
(2004) - et al.
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Lancet
(2001) - et al.
Changing the model of care for patients with acute coronary syndromes
Am Heart J
(2003) The interface of atherosclerosis and thrombosis: basic mechanisms
Vasc Med
(1998)- et al.
Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences
Eur Heart J
(2004) Atherothrombosis as a systemic disease
Cerebrovasc Dis
(2002)- et al.
Evaluation of progression and spread of atherothrombosis
Cerebrovasc Dis
(2002) Reducing risks, promoting healthy lives
(2002)
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review
Circulation
Prevention of atherothrombotic disease network. Critical issues in peripheral arterial disease detection and management: a call to action
Arch Intern Med
Cited by (0)
The REACH Registry is supported by Sanofi-Aventis, Paris, France, Bristol-Myers Squibb, New York, NY, and Waksman Foundation (Japan), Tokyo, Japan. AJR is a statistician employed by Sanofi-Aventis.